News – Page 1162 – Endpoints News

SIGN UP

Roche racks up another checkpoint win as Tecentriq scores in latest PhIII lung cancer study

9 years ago

Sunovion bags PhIII Parkinson’s drug in $624M Cynapsus buyout

9 years ago

Biogen hypes a fresh set of early, upbeat results for Alzheimer’s drug

9 years ago

Scoop: Novartis disbands its pioneering cell and gene therapy unit

9 years ago

$354M exit package in hand, Medivation CEO David Hung completes a master class in biotech auctions

9 years ago

Protocols: With Ninlaro sales suffering, Takeda launches huge multiple myeloma study; Medivir splitting, spinning R&D ...

9 years ago

Abandoned in PhIII, Onconova sacrifices more staffers to its survival strategy

9 years ago

FDA hands Novartis the keys to a $5B Amgen franchise

9 years ago

Protocols: CRO industry poised for steady growth as new work in China explodes (in a good way); Vectura dinged on ...

9 years ago

Neurocrine steers its ‘breakthrough’ tardive dyskinesia drug to an FDA decision

9 years ago

As cardio R&D shrinks in size, a new study highlights some serious pitfalls – and a positive shift

9 years ago

AMRI plans to ax staffers, restructure after completing a $358M buyout

9 years ago

Rigel's positive PhIII for bleeding disorder triggers a roller coaster ride for shares

9 years ago

Protocols: Leap reverse merges with a failing Macrocure; Ferring bags rights to PhIII sciatica drug

9 years ago

Struggling CTI gets a mixed bag of PhIII results for a lead drug still under a full hold at the FDA

9 years ago

A scientist wages a war over women’s 'second-rate' status at the NIH

9 years ago

Martin Shkreli, the obscene prankster of biotech, makes his final exit at KaloBios

9 years ago

Mylan CEO Bresch hopes to tame the mob with a 50% discount for the EpiPen

9 years ago

Booming Moderna is raising $600M while ramping up manufacturing and clinical studies

9 years ago

Protocols: The Mylan furor comes into play for California drug initiative; Adocia concedes a PhIII flop

9 years ago

A radically inexpensive, non-profit approach can transform drug R&D? Now, wait a minute…

9 years ago

Amid layoff fears, AstraZeneca stakes a ‘For Sale’ sign on US campus

9 years ago

Sofinnova Ventures ups the ante - again - as it closes in on $650M biotech fund

9 years ago

Thumbs Up/Thumbs Down: Amgen's silence is deafening; The drug pricing mob is back

9 years ago

First page Previous page 1159 1160 116111621163 1164 1165 Next page Last page